Follow It | Detect Mutations in Plasma

Minimally Invasive. Reliable Results.

Follow It detects mutations that have prognostic or therapeutic value, even when there is insufficient or unavailable tissue for genomic profiling.

Follow It can be used in cases of metastatic disease, unavailable biopsy, insufficient or exhausted tissue, or poor quality DNA.

Maximize your treatment options with Follow It, a cost-effective and robust assay focused on clinically actionable mutations.

Clinical trial Off-label drugs FDA-approved drugs Resistance

Breast Cancer

Gene	Therapeutic Options	Position
AKT1		E17
ERBB2		G309, S310, L755, C805, Exon20
ESR1		K303, S463, V534, P535, L536, Y537, D538
PIK3CA		R88, E542, E545, Q546, D549, M1043, N1044, A1046, H1047, G1049

Colorectal

Gene	Therapeutic Options	Position
BRAF		Q201, G466, F468, G469, Y472, D594, G596, L597, V600, K601
KRAS		G12, G13, A59, Q61, K117, A146
NRAS		G12, G13, A59, Q61, K117, A146
PIK3CA		R88, E542, E545, Q546, D549, M1043, N1044, A1046, H1047, G1049

Endometrial

Gene	Therapeutic Options	Position
CTNNB1		D32, S33, G34, S37, T41, S45
PIK3CA		R88, E542, E545, Q546, D549, M1043, N1044, A1046, H1047, G1049
POLE		Exon9, Exon10, Exon11, Exon12, Exon13, Exon14

Melanoma

Gene	Therapeutic Options	Position
BRAF		Q201, G466, F468, G469, Y472, D594, G596, L597, V600, K601
KIT		Exon9, Exon11, Exon13, T670, D816, D820, N822, Y823, A829
NRAS		G12, G13, A59, Q61, K117, A146

GIST

Gene	Therapeutic Options	Position
BRAF		Q201, G466, F468, G469, Y472, D594, G596, L597, V600, K601
PDGFRA		N659, R560-E571, D842, L839-Y849
KIT		Exon9, Exon11, Exon13, T670, D816, D820, N822, Y823, A829

Glioma

Gene	Therapeutic Options	Position
BRAF		Q201, G466, F468, G469, Y472, D594, G596, L597, V600, K601
IDH1		R132
IDH2		R140, R172

NSCLC

Gene	Therapeutic Options	Position
BRAF		Q201, G466, F468, G469, Y472, D594, G596, L597, V600, K601
EGFR		S492, Exon18, Exon19, Exon20, Exon21
ERBB2		G309, S310, L755, C805, Exon20
KRAS		G12, G13, A59, Q61, K117, A146
MET		Y1253, Exon13, Exon 14 (-50 to +25), Exon18

Sarcoma

Gene	Therapeutic Options	Position
GNAS		R201
IDH1		R132
IDH2		R140, R172

Gene	Position
AKT1	E17
ALK	T1151, L1152, C1156, F1174, L1196, L1198, G1202, D1203, S1206, G1269, R1275
AR	L702H, S741, W742, V716, H875, F877, T878
BRAF	Q201, G466, F468, G469, Y472, D594, G596, L597, V600, K601
CTNNB1	D32, S33, G34, S37, T41, S45
DDR2	L239, I638, S768
EGFR	S492, Exon18, Exon19, Exon20, Exon21
ERBB2	G309, S310, L755, C805, Exon20
ESR1	K303, S463, V534, P535, L536, Y537, D538
GNA11	Q209
GNAQ	Q209
GNAS	R201
HRAS	G12, G13, Q61
IDH1	R132
IDH2	R140, R172
KIT	Exon9, Exon11, Exon13, T670, D816, D820, N822, Y823, A829
KRAS	G12, G13, A59, Q61, K117, A146
MAP2K1(MEK1)	Q56, K57, K59, D67, C121, P124, P387
MAP2K2(MEK2)	F57, Q60, K61, L119
MET	Y1253, Exon13, Exon 14 (-50 to +25), Exon18
NRAS	G12, G13, A59, Q61, K117, A146
PDGFRA	N659, R560-E571, D842, L839-Y849
PIK3CA	R88, E542, E545, Q546, D549, M1043, N1044, A1046, H1047, G1049
POLE	Exon9, Exon10, Exon11, Exon12, Exon13, Exon14
PTCH1	W844, G1093
PTEN	R130
RET	C634, V804, M918
ROS1	L2026, G2032
SMO	D473, S533, W535
TP53	Exon4, Exon5, Exon6, Exon7, Exon8, Exon9

Genes	30
Hotspots	146
Exons	23
Turnaround Time	3-5 days
Mutation types	SNVs, deletions and insertions (up to 24bp)
Sensitivity	>97.6%
Specificity	100%
Assay Cutoff	Below .5% VAF
Average Coverage	10,000x
Assay Reproducibility	94.6%
Sample Type	Blood
Sample Requirement	2 x 10 mL of blood in Streck tubes

Benefits

Actionable Results

Reduce ambiguity by targeting only actionable mutations.

Rapid Turnaround Time

Make clinical decisions faster, with accurate reporting in as little as 3 days.

Comprehensive Reports

Review detailed interpretations, current treatment options, and available clinical trials.

Cost-Effective

Reduce the financial burden on healthcare providers and patients with the most cost-effective ctDNA test* on the market.

*defined by geography

Minimally Invasive

A minimally invasive option for biopsy, Follow It can also be used for unavailable biopsy, insufficient tissue, or poor quality DNA.

Accreditation

All Canexia Health assays were developed under full accreditation of the CAP and CLIA.

View Other Solutions

Find It^®

Tailor treatment decisions based on somatic mutations in your patient’s tumor.

Learn About Find It

Fusions

Rapid, cost-effective, and clinically actionable, Fusions allows you the flexibility to isolate and interrogate relevant fusions.

Learn About Fusions

Canexia Informatics Platform

Each comprehensive report includes detailed results as well as therapeutic recommendations and expertly curated clinical trials. Our insights can help you make more informed treatment decisions.

Learn About Our Reports

Comprehensive Reports, Right From Your Lab

Perform world-leading mutation testing for cancer patients, right from your laboratory. From mutation identification to auto-generated clinical reports, Canexia Health’s proprietary platform puts the control back in your hands.

Learn More

Canadian Access to Follow It

The Canadian Access Program provides access to Follow It, Canexia Health’s blood-based circulating tumor DNA (ctDNA) next-generation sequencing (NGS) hotspot panel. The program is currently open to oncologists and patients in Canada.

View Information for Patients

Recent Resources

In the News

February 4, 2021

Pilot of new cancer test in Canada shows promise as faster alternative to conventional biopsies

This article from The Globe and Mail covers Project ACTT, a federally funded project, led by Canexia Health, which offers the potential for a more efficient alternative for cancer testing that can save hospital resources and lower the risk of infection.

Blog

November 13, 2020

Liquid Biopsy Offers New Hope for Ontario Family

Carla Van Wyck-MacDonald’s cancer had progressed to an advanced stage before she was referred by her oncologist to get a liquid biopsy through Canexia’s Project ACTT. The test revealed a mutation known as PIK3CA, which led to her enrolment in clinical trials for two targeted drugs.

Blog

September 22, 2020

Why Bring Liquid Biopsy Testing In-House? The Case for Millions in Cost Savings

Our recent study discovered that in-house liquid biopsy testing, with an actionable circulating tumor DNA (ctDNA) panel, would enable healthcare organizations to attain substantial cost savings — $2.7M per 1,000 cancer patients.

In the News

July 16, 2020

Canexia Health To Offer Cancer Testing and Treatment During COVID-19

A consortium led by Vancouver’s Canexia Health (formerly Contextual Genomics) will soon offer critical testing and treatment options for Canadian cancer patients during the COVID-19 pandemic.